A Ivanova

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 28:2941-51. 2009
  2. ncbi request reprint Drawbacks to integer scoring for ordered categorical data
    A Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, 27599 7400, USA
    Biometrics 57:567-70. 2001
  3. ncbi request reprint Bivariate isotonic design for dose-finding with ordered groups
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 25:2018-26. 2006
  4. ncbi request reprint Escalation, group and A + B designs for dose-finding trials
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 25:3668-78. 2006
  5. doi request reprint Two-stage designs for Phase 2 dose-finding trials
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599 7420, USA
    Stat Med 31:2872-81. 2012
  6. pmc Adaptive dose finding based on t-statistic for dose-response trials
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, U S A
    Stat Med 27:1581-92. 2008
  7. pmc Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    Biometrics 65:307-15. 2009
  8. doi request reprint An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    J Biopharm Stat 19:247-55. 2009
  9. doi request reprint Optimality, sample size, and power calculations for the sequential parallel comparison design
    Anastasia Ivanova
    Department of Biostatistics, CB 7420, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 30:2793-803. 2011
  10. ncbi request reprint Continuous toxicity monitoring in phase II trials in oncology
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    Biometrics 61:540-5. 2005

Research Grants

  1. Current Design Issues in Oncology Trials
    Anastasia Ivanova; Fiscal Year: 2007

Detail Information

Publications30

  1. pmc An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 28:2941-51. 2009
    ....
  2. ncbi request reprint Drawbacks to integer scoring for ordered categorical data
    A Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, 27599 7400, USA
    Biometrics 57:567-70. 2001
    ..We show that this practice generally leads to unnecessarily conservative tests. The use of slightly perturbed scores will result in a less conservative and uniformly more powerful test...
  3. ncbi request reprint Bivariate isotonic design for dose-finding with ordered groups
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 25:2018-26. 2006
    ..We propose a non-parametric design for this problem. Toxicity is estimated using the bivariate isotonic regression estimator. The new design is compared with the two-sample continual reassessment method...
  4. ncbi request reprint Escalation, group and A + B designs for dose-finding trials
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 25:3668-78. 2006
    ..Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered...
  5. doi request reprint Two-stage designs for Phase 2 dose-finding trials
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599 7420, USA
    Stat Med 31:2872-81. 2012
    ..Simulations show that the proposed two-stage design is superior to equal allocation and to a two-stage strategy where only one dose is left in the second stage...
  6. pmc Adaptive dose finding based on t-statistic for dose-response trials
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, U S A
    Stat Med 27:1581-92. 2008
    ....
  7. pmc Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    Biometrics 65:307-15. 2009
    ..If that difference is close to zero, the dose is repeated. Otherwise, the dose is increased or decreased, depending on the sign of the difference...
  8. doi request reprint An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    J Biopharm Stat 19:247-55. 2009
    ....
  9. doi request reprint Optimality, sample size, and power calculations for the sequential parallel comparison design
    Anastasia Ivanova
    Department of Biostatistics, CB 7420, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 30:2793-803. 2011
    ..As response rates are not known before the trial, a two-stage approach with allocation to active drug in both stages is a robust design choice...
  10. ncbi request reprint Continuous toxicity monitoring in phase II trials in oncology
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    Biometrics 61:540-5. 2005
    ..A table is provided from which Pocock stopping boundaries can be easily obtained for a range of toxicity rates and sample sizes. Estimation of the probability of toxicity and response is also discussed...
  11. ncbi request reprint Improved up-and-down designs for phase I trials
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7420, USA
    Stat Med 22:69-82. 2003
    ..Different estimators of the target dose are compared. We find that the isotonic regression estimator is superior to other estimators for small to moderate sample sizes...
  12. ncbi request reprint Adjusting for observable selection bias in block randomized trials
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, NC 27599, USA
    Stat Med 24:1537-46. 2005
    ..The method allows not only testing for the presence of observable selection bias, but also testing for a difference in treatment effects, adjusting for possible selection bias...
  13. ncbi request reprint A new dose-finding design for bivariate outcomes
    Anastasia Ivanova
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Biometrics 59:1001-7. 2003
    ..We present a new sequential design to maximize the number of subjects assigned in the neighborhood of the optimal safe dose in a dose-finding trial with two outcomes...
  14. ncbi request reprint A non-parametric approach to the design and analysis of two-dimensional dose-finding trials
    Anastasia Ivanova
    Department of Biostatistics, CB 7420, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Stat Med 23:1861-70. 2004
    ..We conclude that the new design and the bivariate isotonic estimator are superior to the procedure where several independent dose-finding trials are run...
  15. ncbi request reprint Two-dimensional dose finding in discrete dose space
    Kai Wang
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7420, USA
    Biometrics 61:217-22. 2005
    ..We show that the new design is more effective in identifying the maximum-tolerated combinations than one-dimensional designs applied at each dose level of one of the agents...
  16. ncbi request reprint A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 17:104-9. 2006
    ..The optimal schedule of taxane administration has been an area of active interest in several recent clinical trials...
  17. doi request reprint A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    E Claire Dees
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 63:99-107. 2008
    ..We conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors...
  18. pmc Physician-patient racial concordance, continuity of care, and patterns of care for hypertension
    Thomas R Konrad
    Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC 27599 7590, USA
    Am J Public Health 95:2186-90. 2005
    ..Physician race had little effect, but continuity is important for successful management of hypertension in older persons...
  19. ncbi request reprint A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients
    Shannon S Carson
    Division of Pulmonary and Critical Care, Department of Medicine, University of North Carolina at Chapel Hill, 4134 Bioinformatics Building, Chapel Hill, NC 27599 7020, USA
    Crit Care Med 34:1326-32. 2006
    ..To compare duration of mechanical ventilation for patients randomized to receive lorazepam by intermittent bolus administration vs. continuous infusions of propofol using protocols that include scheduled daily interruption of sedation...
  20. ncbi request reprint Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
    Robert Z Orlowski
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7295, USA
    Blood 105:3058-65. 2005
    ..Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen...
  21. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  22. ncbi request reprint Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide
    Hanna Kelly
    Department of Medicine, University of North Carolina at Chapel Hill, NC 27599 7305, USA
    Clin Breast Cancer 7:237-43. 2006
    ..This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly paclitaxel after AC (doxorubicin/cyclophosphamide)...
  23. ncbi request reprint The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes
    Jane C Schroeder
    Department of Epidemiology, UNC Linebarger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 1700 Airport Road, Chapel Hill, NC 27599, USA
    Prostate 66:1162-76. 2006
    ..The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a multidisciplinary study of social, individual, and tumor-level causes of racial differences in prostate cancer aggressiveness...
  24. ncbi request reprint Early enteral nutrition does not decrease hypermetabolism associated with burn injury
    Michael D Peck
    Department of Surgery, University of North Carolina Healthcare, Chapel Hill, North Carolina, USA
    J Trauma 57:1143-8; discussion 1148-9. 2004
    ..A prospective, randomized study was performed to compare the effects of early versus late enteral feeding on postburn metabolism...
  25. ncbi request reprint Efficient generation of constrained block allocation sequences
    Ibrahim Salama
    School of Business, North Carolina Central University, 1801 Fayetteville St, Durham, NC 27707, USA
    Stat Med 27:1421-8. 2008
    ..We propose an algorithm that efficiently generates constrained block allocation sequences, and we describe two clinical trials in which such a constrained randomization was used...
  26. ncbi request reprint Minimizing predictability while retaining balance through the use of less restrictive randomization procedures
    Vance W Berger
    National Cancer Institute, EPN, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Stat Med 22:3017-28. 2003
    ..This feature makes the maximal procedure more resistant to selection bias than the randomized block procedure is...
  27. ncbi request reprint Sequential urn designs with elimination for comparing K > or =3 treatments
    D Stephen Coad
    Department of Mathematics, University of Sussex, Falmer, Brighton BN1 9RF, U K
    Stat Med 24:1995-2009. 2005
    ..It is then shown how the sequential elimination procedure may be used in dose-finding studies and its performance is compared with a recently proposed method. Several possible extensions to the work are briefly indicated...
  28. ncbi request reprint The use of the triangular test with response-adaptive treatment allocation
    D Stephen Coad
    Department of Mathematics, University of Sussex, Falmer, Brighton BN1 9RF, UK
    Stat Med 24:1483-93. 2005
    ..The results of an AIDS trial are used to illustrate the performance of the triangular test when combined with the drop-the-loser rule...
  29. ncbi request reprint The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population
    Mary Ann Knovich
    Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Br J Nutr 99:1226-9. 2008
    ..On the other hand, the finding of hypocupraemia in a subset of adults with unexplained anaemia suggests that Cu deficiency may be a common reversible cause of anaemia in adults...
  30. ncbi request reprint Traditional design does not choose values around 33%
    Anastasia Ivanova
    Control Clin Trials 23:183. 2002

Research Grants3

  1. Current Design Issues in Oncology Trials
    Anastasia Ivanova; Fiscal Year: 2007
    ..The goal is to develop a study design to identify the dose with a target weighted average of the rates of different toxicity grades. (4) The fourth setting is a genome-wide association study. ..